Oppenheimer Holdings, Inc. Increases Chemed Corp. (CHE) Price Target to $225.00

Chemed Corp. (NYSE:CHE) had its price target upped by Oppenheimer Holdings, Inc. from $220.00 to $225.00 in a research report report published on Friday, October 27th. Oppenheimer Holdings, Inc. currently has an outperform rating on the stock.

Other analysts have also recently issued reports about the company. Zacks Investment Research raised Chemed Corp. from a hold rating to a buy rating and set a $213.00 price objective on the stock in a research report on Wednesday, August 23rd. TheStreet cut Chemed Corp. from a b+ rating to a c+ rating in a research report on Tuesday, July 25th. BidaskClub cut Chemed Corp. from a buy rating to a hold rating in a research report on Wednesday, August 2nd. Finally, Royal Bank Of Canada reaffirmed a hold rating and set a $209.00 price objective on shares of Chemed Corp. in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of C$236.00.

Chemed Corp. (NYSE:CHE) traded down C$0.01 during midday trading on Friday, hitting C$231.12. The company had a trading volume of 97,500 shares, compared to its average volume of 93,727. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $3,690.06, a PE ratio of 28.46, a PEG ratio of 4.89 and a beta of 1.14. Chemed Corp. has a 12 month low of C$143.87 and a 12 month high of C$235.96.

Chemed Corp. (NYSE:CHE) last posted its earnings results on Thursday, October 26th. The company reported C$2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C$2.00 by C$0.15. The company had revenue of C$417.40 million for the quarter, compared to analysts’ expectations of C$414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. Chemed Corp.’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $1.73 earnings per share. equities analysts anticipate that Chemed Corp. will post 4.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Oppenheimer Holdings, Inc. Increases Chemed Corp. (CHE) Price Target to $225.00” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/chemed-corp-che-given-new-225-00-price-target-at-oppenheimer-holdings-inc.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Monday, November 13th will be issued a dividend of $0.28 per share. The ex-dividend date is Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.48%. Chemed Corp.’s payout ratio is 24.89%.

In other news, VP Naomi C. Dallob sold 1,900 shares of Chemed Corp. stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of C$231.00, for a total transaction of C$438,900.00. Following the completion of the transaction, the vice president now directly owns 10,426 shares in the company, valued at C$2,408,406. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald E. Saunders sold 500 shares of Chemed Corp. stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of C$227.75, for a total transaction of C$113,875.00. Following the transaction, the director now owns 10,298 shares of the company’s stock, valued at C$2,345,369.50. The disclosure for this sale can be found here. Insiders have sold 15,650 shares of company stock valued at $3,480,193 over the last quarter. Company insiders own 4.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC purchased a new position in Chemed Corp. in the 2nd quarter worth approximately $120,000. Pacad Investment Ltd. raised its holdings in Chemed Corp. by 250.0% in the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after acquiring an additional 500 shares during the last quarter. IFP Advisors Inc raised its holdings in Chemed Corp. by 1,504.5% in the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Chemed Corp. by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares during the last quarter. Finally, MCF Advisors LLC purchased a new position in Chemed Corp. in the 3rd quarter worth approximately $152,000. Hedge funds and other institutional investors own 96.58% of the company’s stock.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply